GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks

  • GSK plc GSK and Scynexis Inc SCYX have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets).
  • The FDA approved the antifungal for vulvovaginal candidiasis (VVC) and reduced the incidence of recurrent VVC (RVVC). 
  • This exclusive agreement gives GSK rights to commercialize Brexafemme for VVC and RVVC while continuing to develop ibrexafungerp, which is in phase 3 trials for potentially treating invasive candidiasis (IC), which affects the blood or internal organs.
  • Scynexis has been looking for a partner after it said last October that it was winding down promotional activities for the drug and announced workforce reduction.
  • Infectious diseases and HIV represent around two-thirds of GSK's pipeline. Brexafemme complements GSK's pipeline alongside late-stage antibiotics gepotidacin and tebipenem.
  • GSK will make an upfront payment to Scynexis of $90 million.
  • Scynexis is due to get $245.5 million in development, regulatory and commercial milestones there — with a separate $15 million tied to an FDA approval. Sales-related milestones add up to another $242.5 million.
  • Price Action: SCYX shares are up 64.70% at $2.75 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!